Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q1 2025
Institutional positions in Definium Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 191
- +18 vs. Q4 2024
- Shares held
- 41.2M
- −58.8K (−0.1%) vs. Q4 2024
- Total value
- $240.5M
- −$46.4M (−16.2%) vs. Q4 2024
- New holders
- 39
- 50 more added
- Sold out
- 21
- 46 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DFTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 362 | $5.35B |
| Q1 2026 | 248 | $1.47B |
| Q4 2025 | 209 | $908.7M |
| Q3 2025 | 196 | $468.6M |
| Q2 2025 | 183 | $271.0M |
| Q1 2025 | 191 | $240.5M |
| Q4 2024 | 174 | $288.9M |
| Q3 2024 | 158 | $281.6M |
| Q2 2024 | 152 | $299.3M |
| Q1 2024 | 135 | $327.2M |
| Q4 2023 | 104 | $17.9M |
| Q3 2023 | 93 | $12.1M |
| Q2 2023 | 84 | $13.9M |
| Q1 2023 | 89 | $12.6M |
| Q4 2022 | 104 | $11.1M |
| Q3 2022 | 101 | $20.5M |
| Q2 2022 | 156 | $15.1M |
| Q1 2022 | 159 | $53.6M |
| Q4 2021 | 176 | $72.0M |
| Q3 2021 | 175 | $104.8M |
| Q2 2021 | 156 | $131.0M |
| Q1 2021 | 8 | $932.0K |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Definium Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SLT Holdings LLC | 0 | $0 | 0.00% | −13,100−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −10,127−100.0% | Sold out |
| Militia Capital Partners, LP | 0 | $0 | 0.00% | −7,400−100.0% | Sold out |
| Diadema Partners LP | 0 | $0 | 0.00% | −4,710−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −1,040−100.0% | Sold out |
| Venturi Wealth Management, LLC | 0 | $0 | 0.00% | −721−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −533−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −450−100.0% | Sold out |
| Cornerstone Planning Group LLC | 0 | $0 | 0.00% | −77−100.0% | Sold out |
| Kohmann Bosshard Financial Services, LLC | 0 | $0 | 0.00% | −66−100.0% | Sold out |
| Glen Eagle Advisors, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Coppell Advisory Solutions LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |